Search
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalTPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well … Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730].
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexSofpironium
go.drugbank.com/drugs/DB19325ApprovedSofpironium is a "soft" anticholinergic analog of [glycopyrronium] that has been modified with a readily hydrolyzable ester moiety. … [L51109] Soft drugs are designed to reduce systemic toxicity while enhancing local efficacy by employing retrometabolic drug design, in which a molecule contains a metabolically sensitive moiety that promotes
Human interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalHuman interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … [L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalZuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABA<sub>A</sub> receptors. … [A260776,A260786] Zuranolone was designed with a pharmacological profile of a neuroactive steroid in mind while also possessing a pharmacokinetics profile of an oral, once-daily dosing formulation.
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive ModulatorVigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual … Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active.
Linezolid
go.drugbank.com/drugs/DB00601ApprovedInvestigational[A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor. … Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: LINEZOLID 1A PHARMA 600MG, Linezolid 1A Pharma 600 mg – FilmtablettenTrimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[L33015] Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s. … [A233215] Trimetazidine is not FDA approved. However, it has been approved in France since 1978.[L33020]
Eluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalEluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). … reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D.
REC-994
go.drugbank.com/drugs/DB15616InvestigationalREC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).